艾欧凡斯生物治疗 IOVA
$8.04 +$0.30 (+3.88%)
休市 · Nov 7, 10:00 pm ET · 最新盘后价 $8.05 +0.07%
开盘$8.10
昨收$7.74
当日区间$7.72 – $8.28
成交量12.96M
市值$3.72B
市盈率（TTM）–
股息率–
财报
财报日平均波动±17.9%近16次财报
收涨次数7 / 1644% 的概率
最佳反应+43.1%
最差反应-44.8%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 6 Aug 2026 | Pre Market | ±29.7% | +43.09% | 超出定价预期 |
| 2026/Q1 | 7 May 2026 | Pre Market | ±15.8% | -13.20% | 符合区间 |
| 2025/Q4 | 24 Feb 2026 | Pre Market | ±18.3% | +30.80% | 超出定价预期 |
| 2025/Q3 | 6 Nov 2025 | Pre Market | ±24.9% | +27.62% | 超出定价预期 |
| 2025/Q2 | 7 Aug 2025 | After Market | ±34.9% | -20.08% | 符合区间 |
| 2025/Q1 | 8 May 2025 | After Market | ±27.4% | -44.80% | 超出定价预期 |
| 2024/Q4 | 27 Feb 2025 | After Market | ±25.1% | -19.49% | 符合区间 |
| 2024/Q3 | 7 Nov 2024 | After Market | ±19.1% | -13.80% | 符合区间 |
| 2024/Q2 | 8 Aug 2024 | After Market | ±29.9% | +24.94% | 符合区间 |
| 2024/Q1 | 9 May 2024 | After Market | ±17.7% | -18.48% | 超出定价预期 |
| 2023/Q4 | 28 Feb 2024 | After Market | ±11.8% | -8.72% | 符合区间 |
| 2023/Q3 | 7 Nov 2023 | After Market | ±24.7% | -3.47% | 符合区间 |
| 2023/Q2 | 8 Aug 2023 | After Market | ±20.4% | +6.44% | 符合区间 |
| 2023/Q1 | 9 May 2023 | After Market | ±19.7% | +3.80% | 符合区间 |
| 2022/Q3 | 3 Nov 2022 | After Market | ±27.0% | +4.34% | 符合区间 |
| 2022/Q2 | 4 Aug 2022 | After Market | ±19.8% | -2.87% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
营收构成
2026/Q2 季度
按业务线
基本面
最新报告季度：Q2, ended Jun 2026
营收$99.31M+65.7% YoY
营业利润-$51.91M+54.4% YoY
净利润-$47.32M+57.6% YoY
摊薄每股收益-$0.11+66.7% YoY
自由现金流-$66.28M+11.5% YoY
经营现金流-$60.84M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率48.4%
营业利润率-91.1%
净利率-89.1%
净资产收益率-40.7%
资产收益率-31.8%
投入资本回报率-39.3%
流动比率4.35
负债/资产比率19.6%
现金及投资$110.77M
总负债$43.33M
净现金（净负债）$67.44M
暂无评论——快来第一个聊聊 IOVA。
登录后参与讨论。